These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22147798)

  • 1. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.
    Steele J; Chen K; Sun X; Zhang Y; Wang H; Tzipori S; Feng H
    J Infect Dis; 2012 Feb; 205(3):384-91. PubMed ID: 22147798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
    Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
    Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enterotoxicity of Clostridium difficile toxins.
    Sun X; Savidge T; Feng H
    Toxins (Basel); 2010 Jul; 2(7):1848-80. PubMed ID: 22069662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum.
    Sprague R; Warny K; Pollock N; Daugherty K; Lin Q; Xu H; Cuddemi C; Barrett C; Chen X; Banz A; Lantz A; Garey KW; Gonzales-Luna AJ; Alonso CD; Galvez JAV; Kelly CP
    Dig Dis Sci; 2021 Oct; 66(10):3303-3306. PubMed ID: 33164145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile toxins and severe C. difficile infection.
    Johnson S
    J Infect Dis; 2012 Feb; 205(3):353-4. PubMed ID: 22147800
    [No Abstract]   [Full Text] [Related]  

  • 10. Extra-Intestinal Effects of
    Tonon F; Di Bella S; Grassi G; Luzzati R; Ascenzi P; di Masi A; Zennaro C
    Cells; 2020 Dec; 9(12):. PubMed ID: 33271969
    [No Abstract]   [Full Text] [Related]  

  • 11. Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.
    Di Bella S; Ascenzi P; Siarakas S; Petrosillo N; di Masi A
    Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
    Schmidt DJ; Beamer G; Tremblay JM; Steele JA; Kim HB; Wang Y; Debatis M; Sun X; Kashentseva EA; Dmitriev IP; Curiel DT; Shoemaker CB; Tzipori S
    Clin Vaccine Immunol; 2016 Sep; 23(9):774-84. PubMed ID: 27413067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of toxemia in patients with Clostridium difficile infection.
    Yu H; Chen K; Wu J; Yang Z; Shi L; Barlow LL; Aronoff DM; Garey KW; Savidge TC; von Rosenvinge EC; Kelly CP; Feng H
    PLoS One; 2015; 10(4):e0124235. PubMed ID: 25885671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
    Steele J; Parry N; Tzipori S
    Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
    Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
    Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
    Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
    Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse relapse model of Clostridium difficile infection.
    Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
    Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
    Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
    Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
    Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
    Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.